**1. Introduction**

Over a quarter of a million women are diagnosed with epithelial ovarian cancer (EOC1 ) each year and it is responsible for around 140,000 deaths worldwide. There is no effective screening program so the majority present with advanced disease. Despite improved surgical technique most patients are never cured. Novel systemic treatments are needed both to prolong overall survival *with* the disease but also increase the fraction of patients in whom cure is achieved. A variety of distinct but complementary approaches are discussed here.

1 In this chapter, EOC refers also to primary peritoneal and fallopian tube carcinoma. Definitions of platinum-sensitive, resistant and refractory are as per the relevant citation.

Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
